Navigation Links
EquitiesIQ Initiates Coverage of Alliqua, Inc.
Date:1/14/2014

New York, NY (PRWEB) January 14, 2014

EquitiesIQ, a leading informational research provider, has initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, developing, manufacturing, and marketing proprietary products to serve the wound care market.

Free report download: http://equitiesiq.com/reports/alliqua/

In late 2012, Alliqua was restructured with a seasoned management team and Board, which launched the company’s new strategy to become a leading provider of wound care products. Coincident with the new leadership, Alliqua raised capital from company insiders along with a group of retail and institutional investors. With this initial capital, Alliqua began to build its sales infrastructure and consolidate its operations.

Throughout 2013, the company entered strategic relationships with a variety of wholesale distributors including Team Distribution International, World Health Industries, McKesson Medical-Surgical, and Medline. Alliqua also secured a license agreement with sorbion GmbH & Co. to distribute wound care dressings based on sorbion’s proprietary hydroactive technology.

In November 2013, the company entered into an agreement with Celgene Corporation (CELG) to develop and market wound healing products based on Celgene Cellular Thereapeutics’ (CCT) placenta-derived technology. Products based on this technology are anticipated to have superior wound-healing characteristics, and will enable Alliqua to enter one of the fastest growing segments of the wound care market. In conjunction with the Celgene license agreement, a group of healthcare-focused institutional investors, and Celgene itself, collectively made a $14 million equity investment into the company.

Well capitalized, with its own line of value-added hydrogels, the sorbion wound care dressings, and the tissue based wound healing products from Celgene, Alliqua is now positioned to address a spectrum of wounds with a broad line of innovative solutions.

The full Initiation Report is available to download at the EquitiesIQ website. EquitiesIQ will provide ongoing coverage and event-based updates as developments occur.

Free report download: http://equitiesiq.com/reports/alliqua/

About EquitiesIQ

EquitiesIQ publishes and distributes research reports that enhance the visibility of our client companies. Our reports are written by analysts who recognize investors’ desire to understand a business in a way that supports an educated investment decision. To learn more about EquitiesIQ, visit the company's website, http://equitiesiq.com. EquitiesIQ is not a registered investment adviser or broker-dealer.

Important Disclosures and Disclaimers

The research report described in this press release has been prepared by EquitiesIQ, LLC on behalf of Alliqua, Inc. (the “Company”), as part of investor relations services provided to Alliqua by EquitiesIQ. EquitiesIQ has been compensated for preparation of the research report and for future coverage, as fully disclosed in the report. David Moskowitz is the author of the report and the views regarding Alliqua expressed in the report accurately reflect the personal views of Mr. Moskowitz regarding Alliqua and its securities, as of the date of the report.

The research report is not an offer or solicitation to buy or sell the securities of the Alliqua. This report is for information purposes only, and is not intended to (and is provided explicitly on the condition that it not) be used as the sole basis to make any investment decision. Investors should make their own determinations whether an investment in any particular security is consistent with their investment objectives, risk tolerance, and financial situation. EquitiesIQ and its affiliates are not recommending any investments based on the information in the research report.

Forward-looking Statements

This press release and the research report contain forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. EquitiesIQ does not guarantee the accuracy and comprehensiveness of these predictions. You should not invest in the Alliqua in reliance on these forward-looking statements.

Please read the full disclosures and disclaimers at the end of the report as well as the general disclaimers and terms at http://equitiesiq.com/disclaimer.

Read the full story at http://www.prweb.com/releases/2014/01/prweb11485599.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
2. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
3. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
4. Applied Genetics Initiates Commercial Operation
5. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
6. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
7. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
8. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
9. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
10. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
11. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. The ... Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, industry ... officials from around the world to address key issues in device compliance, quality and ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the main ... people each year. Especially those living in larger cities are affected by air pollution ... of the most pollution-affected countries globally - decided to take action. , “I knew ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... CRUZ, Calif. , Oct. 10, 2017 ... grant from the NIH to develop RealSeq®-SC (Single Cell), ... kit for profiling small RNAs (including microRNAs) from single ... Analysis Program highlights the need to accelerate development of ... "New techniques for measuring ...
Breaking Biology Technology:
(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... Apr. 11, 2017 Research and Markets has ... report to their offering. ... The global eye tracking market to grow at a CAGR of ... Eye Tracking Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Biology News(10 mins):